New Enterprise Associates (NEA)

What they fund

Companies across all stages from idea to IPO, with a focus on technology and healthcare [1]., Firms leveraging vertical AI and personal intelligence applications [1]., Biopharma and healthcare companies, with significant historical investment in this sector [2]., Global companies, with offices in Menlo Park, London, New York, and affiliates in Mumbai, Bangalore, Beijing, and Shanghai [2].

Investment thesis

NEA crafts enduring partnerships with ambitious founders at every stage of company building, prioritizing relationships over momentary investments in ideas [1]. The firm focuses on technology and healthcare, exploring the outer edges of possibility in these sectors [1]. Recent strategic themes include "Tomorrow’s Titans: Vertical AI" and "Consumer AI: Personal Intelligence," indicating a thesis centered on emerging AI applications [1]. They also analyze "Overlooked Case Studies from Public Markets" to inform their investment approach [1].

Credibility: NEA website homepage and blog posts (02.05.25, 01.14.25, 02.20.25) [1].

Value add

NEA offers a relationship-first approach, crafting enduring partnerships with founders [1]. They provide deep insight and diverse perspectives to support company building [1].

Fit verdict: Ideal for founders seeking a long-term partner with a global reach and deep expertise in technology and healthcare.

Founder diligence script:

• How does NEA's relationship-first approach translate into active support during scaling phases?
• What specific AI or healthcare expertise does the firm bring to my company?
• How does NEA leverage its global network to open new markets for portfolio companies?

Portfolio focus

Biopharma and healthcare: Acadia Pharmaceuticals, Adaptimmune, Amicus Therapeutics, Clovis Oncology, Tesaro [2]., Technology and AI: Databricks [2]., Historical tech: 3Com (1981) [2].

Notable investments & exits

Over 650 liquidity events, including over 250 IPOs and 300 acquisitions [2]., 3Com (1981) - early investment and liquidity event [2]., Acadia Pharmaceuticals, Adaptimmune, Amicus Therapeutics, Clovis Oncology, Tesaro - recent investments with potential exits [2].

Strategic implications

NEA's massive AUM and long history provide unparalleled resources for portfolio companies, but may also lead to a focus on later-stage, large-cap deals. Their strong healthcare and technology focus creates a deep expertise moat, but may limit diversification. The relationship-first thesis is a key differentiator, but its execution and impact on founder success are critical to monitor.

Where they could go further

NEA could deepen its engagement with early-stage AI startups, given the current trend towards vertical AI., Expanding its network in emerging markets, particularly in Asia, could unlock new growth opportunities for portfolio companies., Enhancing its post-investment support for healthcare companies, particularly in regulatory navigation, could add significant value., NEA could leverage its public market insights to better guide portfolio companies towards successful exits.